Cardiol Therapeutics (CRDL)
Develops oral and injectable therapies for inflammatory heart disease.
$2.18
Pre-market+0.02 (+0.69%)
At close$2.17(+0.70%)
In millions of USD, except per-share figures · converted from CAD at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 4 | 6 | 4 | 10 | 5 | 6 | 6 | 7 | 6 | 7 | 8 | |
| Research & development | 1 | 2 | 2 | 1 | 3 | 2 | 3 | 2 | 3 | 2 | 4 | 3 |
| 3 | 2 | 4 | 3 | 7 | 3 | 3 | 4 | 4 | 4 | 3 | 5 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 4 | 0 | 7 | 0 | 3 | 4 | 4 | 4 | 0 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −4 | −6 | −4 | −10 | −5 | −6 | −6 | −7 | −6 | −7 | −8 |
| 1 | 0 | −1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | −1 | 2 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | 0 | 1 | −1 | −1 | −1 | 0 | 0 | 0 | −1 | 1 | −2 |
| Income before tax | −3 | −4 | −7 | −3 | −9 | −4 | −6 | −6 | −7 | −5 | −8 | −6 |
| Net income from continuing operations | −3 | −4 | −7 | −3 | −9 | −4 | −6 | −6 | −7 | −5 | −8 | −6 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −3 | −4 | −7 | −3 | −9 | −4 | −6 | −6 | −7 | −5 | −8 | −6 |
| EPS, basic | −$0.07 | −$0.09 | −$0.10 | −$0.07 | −$0.13 | −$0.09 | −$0.07 | −$0.07 | −$0.09 | −$0.05 | −$0.07 | −$0.05 |
| EPS, diluted | −$0.07 | −$0.09 | −$0.10 | −$0.07 | −$0.13 | −$0.09 | −$0.07 | −$0.07 | −$0.09 | −$0.05 | −$0.07 | −$0.05 |
| Weighted average shares, basic | 64 | 65 | 67 | 69 | 70 | 70 | 83 | 83 | 85 | 100 | 109 | 115 |
| Weighted average shares, diluted | 64 | 65 | 67 | 69 | 70 | 70 | 83 | 83 | 85 | 100 | 109 | 115 |
| EBITDA | −3 | −4 | −7 | −3 | −9 | −4 | −6 | −6 | −7 | −5 | −8 | −6 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −4 | −7 | −3 | −9 | −4 | −6 | −6 | −7 | −5 | −8 | −6 |